Cargando…
AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20)
BACKGROUND: Loss of PTEN function leads to increased PI3Kβ signaling. AZD8186, a selective PI3Kβ/δ inhibitor, has shown anti-tumor activity in PTEN-deficient preclinical models. This phase 1b/2 study was conducted to determine the safety and efficacy of AZD8186 and paclitaxel combination in patients...
Autores principales: | Suh, Koung Jin, Ryu, Min-Hee, Zang, Dae Young, Bae, Woo Kyun, Lee, Hye Seung, Oh, Hyeon Jeong, Kang, Minsu, Kim, Ji-Won, Kim, Bum Jun, Mortimer, Peter G S, Kim, Hee Jung, Lee, Keun-Wook |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485284/ https://www.ncbi.nlm.nih.gov/pubmed/37036671 http://dx.doi.org/10.1093/oncolo/oyad059 |
Ejemplares similares
-
A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First‐line Therapy (KCSG ST10‐01)
por: Lee, Keun‐Wook, et al.
Publicado: (2018) -
Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
por: Grierson, Patrick M, et al.
Publicado: (2022) -
A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer
por: Ryu, Min‐Hee, et al.
Publicado: (2017) -
A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab‐Paclitaxel and Gemcitabine in Advanced Solid Tumors
por: Beatty, Gregory L., et al.
Publicado: (2018) -
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
por: Choudhury, Atish D., et al.
Publicado: (2022)